M.t.e Pathogenix
AI biosensing monitor for real-time indoor AIrborne pathogen and pollutant detection.
Company Overview
Snapshot
Founded in February 2025, M.t.e Pathogenix operates with 1–10 employees. The company is currently in the Pre-Funding stage, developing an AI-powered indoor air monitoring device.
Business overview
M.t.e Pathogenix, also known as Pathogenix.AI (Senzi.me), develops an AI-powered indoor air monitoring device designed for real-time detection and neutralization of airborne pathogens and pollutants. The product targets both residential and commercial environments, including healthcare, education, and transportation, aiming to mitigate exposure risks by providing alerts and actionable air-safety insights. The solution is positioned as a plug-in monitor focused on rapid detection to promote healthier indoor spaces within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices.
Log in to access full profile ›Company Intelligence Q&A
- When was M.t.e Pathogenix founded?
- M.t.e Pathogenix was founded in February 2025.
- What is the primary focus of M.t.e Pathogenix's technology?
- M.t.e Pathogenix focuses on developing an AI biosensing monitor for real-time detection of indoor airborne pathogens and pollutants.
- What markets does M.t.e Pathogenix target?
- M.t.e Pathogenix targets homes and commercial environments such as healthcare, education, and transportation.
- What is the primary sector of M.t.e Pathogenix?
- M.t.e Pathogenix operates primarily within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices.